NEW YORK--(BUSINESS WIRE)--AdhereTech, an innovative company that improves the patient experience with real-time technology and Smart devices for optimal medication benefits, today announced a strategic partnership with Belgium-based AARDEX Group, the world leader in medication adherence solutions. The collaboration will link AARDEX’s proprietary Medication Event Monitoring System (MEMS®) with AdhereTech's Smart Adherence System, featuring the AdhereTech Smart Pill Bottle.
In clinical trials, nonadherence to medication leads to increased patient drop offs, delayed approval, and diminished efficacy to the point of trial failure. Combining AdhereTech’s connected devices with the MEMS® Adherence Software (MEMS AS®) provides the opportunity to help patients adhere to their dosing regimens through early intervention. As a Smart Devices Partner, AdhereTech participates in AARDEX’s ever-growing ecosystem of MEMS® Adherence Hardware.
“Our technology helps provide a continuous connection between trial organizers and their patients, ensuring regulated dose behavior and immediate intervention when necessary,” said Josh Stein, cofounder and president of AdhereTech. “The combination of our real-time data from AdhereTech’s Smart Adherence System with AARDEX MEMS AS® will help to improve medication adherence in the important area of clinical trials.”
AdhereTech optimizes patient adherence with its revolutionary Smart Pill Bottle, which offers an intuitive experience that is easy to use right out of the box. AdhereTech’s proprietary Smart Pill Bottle and 2-way messaging platform keeps patients on track with their medication protocol while enabling real-time connection between visits, sending alerts to site coordinators when adherence interventions are necessary.
MEMS AS®, developed by AARDEX, is a flexible, online web solution providing sound analysis of medication-taking behaviors for powerful visualization and focused feedback for the patient. It can be connected and integrated into third-party applications for risk stratification and patient empowerment.
“Medication nonadherence has huge implications, not just for commercialized treatments and real-world conditions but also for clinical trials,” said David Dalla Vecchia, CEO and Financial Lead of AARDEX Group. “AdhereTech’s software and data technologies offer an opportunity for early intervention and increased adherence. This partnership adds to our existing strong portfolio of collaborations, allowing us to offer end-to-end patient noncompliance solutions.”
About AARDEX Group
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. With operations in Belgium, Switzerland, and the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. AARDEX’s vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
AdhereTech is a cloud-based software and devices company that seamlessly connects patients to care. Committed to improving the patient experience, AdhereTech’s clinically proven technologies provide easy to use adherence support and real-time connection for patients and their caregivers. AdhereTech partners with many of the world’s leading healthcare companies supporting tens of thousands of patients in commercial, clinical trial, and academic settings. AdhereTech’s medication adherence programs are customized using real-time data from our pioneering smart devices to help patients effortlessly stick to their medication schedules. For more information, please visit AdhereTech’s website at www.adheretech.com.